Neurocrine Biosciences Stock Total Debt
| NBIX Stock | USD 138.89 2.90 2.13% |
Neurocrine Biosciences fundamentals help investors to digest information that contributes to Neurocrine Biosciences' financial success or failures. It also enables traders to predict the movement of Neurocrine Stock. The fundamental analysis module provides a way to measure Neurocrine Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurocrine Biosciences stock.
Total Debt To Capitalization is likely to drop to 0.15 in 2024. Neurocrine | Total Debt |
Neurocrine Biosciences Company Total Debt Analysis
Neurocrine Biosciences' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Neurocrine Biosciences Total Debt | 428.4 M |
Most of Neurocrine Biosciences' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurocrine Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Neurocrine Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Neurocrine Biosciences is extremely important. It helps to project a fair market value of Neurocrine Stock properly, considering its historical fundamentals such as Total Debt. Since Neurocrine Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurocrine Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurocrine Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Neurocrine Total Debt Historical Pattern
Today, most investors in Neurocrine Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neurocrine Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Neurocrine Biosciences total debt as a starting point in their analysis.
Neurocrine Biosciences Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Neurocrine Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Neurocrine Biosciences has a Total Debt of 428.4 M. This is 84.43% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is 91.94% higher than that of the company.
Neurocrine Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurocrine Biosciences' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics of similar companies.Neurocrine Biosciences is currently under evaluation in total debt category among related companies.
Neurocrine Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Neurocrine Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Neurocrine Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Neurocrine Biosciences' value.| Shares | Goldman Sachs Group Inc | 2023-12-31 | 1.4 M | Dodge & Cox | 2023-12-31 | 1.3 M | Dsm Capital Partners Llc | 2023-12-31 | 1.2 M | Pictet Asset Manangement Sa | 2023-12-31 | 1.2 M | Deerfield Management Co | 2023-09-30 | 1.2 M | Wellington Management Company Llp | 2023-12-31 | 1.2 M | Rock Springs Capital Management Lp | 2023-12-31 | 1.2 M | Brown Advisory Holdings Inc | 2023-12-31 | 1.1 M | Armistice Capital, Llc | 2023-12-31 | 1 M | Blackrock Inc | 2023-12-31 | 13.6 M | Vanguard Group Inc | 2023-12-31 | 9.7 M |
Neurocrine Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0878 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 12.96 B | ||||
| Shares Outstanding | 100.58 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 94.71 % | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | 202.90 X | ||||
| Price To Book | 6.07 X | ||||
| Price To Sales | 7.18 X | ||||
| Revenue | 1.89 B | ||||
| Gross Profit | 1 B | ||||
| EBITDA | 416.1 M | ||||
| Net Income | 249.7 M | ||||
| Cash And Equivalents | 799.4 M | ||||
| Cash Per Share | 8.31 X | ||||
| Total Debt | 428.4 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 2.48 X | ||||
| Book Value Per Share | 22.61 X | ||||
| Cash Flow From Operations | 389.9 M | ||||
| Short Ratio | 2.26 X | ||||
| Earnings Per Share | 2.48 X | ||||
| Price To Earnings To Growth | 0.44 X | ||||
| Target Price | 153.29 | ||||
| Number Of Employees | 1.4 K | ||||
| Beta | 0.28 | ||||
| Market Capitalization | 13.68 B | ||||
| Total Asset | 3.25 B | ||||
| Retained Earnings | (157.1 M) | ||||
| Working Capital | 952.2 M | ||||
| Current Asset | 384.07 M | ||||
| Current Liabilities | 25.71 M | ||||
| Net Asset | 3.25 B |
About Neurocrine Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurocrine Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Neurocrine Biosciences Piotroski F Score and Neurocrine Biosciences Altman Z Score analysis. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 2.48 | Revenue Per Share 19.315 | Quarterly Revenue Growth 0.25 | Return On Assets 0.0878 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.